We found that both AMPA and kainate autoreceptors were present on the glutamate-releasing terminals of cerebellar parallel/climbing fibres, and that they functioned as facilitatory autoreceptors. Extracellular cGMP inhibited the neurotransmitter release evoked by presynaptic kainate receptor activation; the inhibitory effect of extracellular cGMP was selective for the kainate autoreceptor-mediated response and did not affect the AMPA autoreceptor-mediated response. Endogenously synthesized cGMP might be the physiological source for the extracellular cGMP modulating the response to kainate autoreceptor activation.
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Introduction
It has long been known that intracellular cyclic GMP (cGMP), whose production is linked through nitric oxide formation to the activation of cerebellar glutamatergic transmission, functions as a crucial cerebellar intracellular messenger, e.g. in the long-term depression of excitatory transmission at parallel fibre-Purkinje cell synapses (see Ito and Karachot, 1992; Boxall and Garthwaite, 1996; Daniel et al., 1998; Hartell, 2001 and references therein). It is also known that cGMP can be actively transported from the intracellular compartment to extracellular fluid through membrane transport proteins (including a probenecid-sensitive transporter and members of the multidrug-resistance protein family; Sager, 2004) . Activation of glutamate receptors has been shown to increase intracellular cGMP levels and to cause cGMP release from the intracellular to the extracellular compartment in cultured cerebellar neurons (Montoliu et al., 1999) or in cerebellar slices (in a probenecid-sensitive way; Tjörnhammar et al., 1986) , the extracellular cGMP levels matching the intracellular levels. Indeed, extracellular cGMP has been exploited in in vivo models as a reliable measure of activation of cerebellar glutamatergic transmission (Wood and Rao, 1991; Luo et al., 1994; Fedele and Raiteri, 1999) . Nevertheless, the roles of extracellular cGMP in the cerebellum have hardly been studied. Interference of cGMP with the response to activation of ionotropic glutamate receptors has been occasionally reported in cultured cerebellar cells; extracellular cGMP has been reported to inhibit glutamate responses at AMPA/kainate receptors in Purkinje cells and in granules (Linden et al., 1995; Poulopoulou and Nowak, 1998) and to prevent glutamate neurotoxicity in cerebellar neurons (Montoliu et al., 1999) . It has also been reported to inhibit binding to a kainate low-affinity site in rat cerebellum membranes (Migani et al., 1997) .
We investigated the ability of extracellular cGMP to interfere with AMPA/kainate receptor responses in the adult cerebellum, by using superfused purified synaptosomes, which This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on September 30, 2009 as DOI: 10.1124 at ASPET Journals on October 18, 2017 jpet.aspetjournals.org Downloaded from JPET #154955 5 allow direct functional evidence of presynaptic release-regulating receptors. Two aspects were investigated: 1) the presence and functioning of AMPA and kainate autoreceptors on the glutamatergic terminals of rat cerebellar parallel/climbing fibres; 2) the effect of extracellular cGMP on presynaptic AMPA and kainate autoreceptor-mediated effects. We found that activating ionotropic glutamate autoreceptors belonging to both AMPA and kainate subtypes stimulated glutamate release from the terminals of rat cerebellar parallel/climbing fibres, which fits in with electrophysiological evidence of the presence of presynaptic AMPA/kainate autoreceptors on the glutamate-releasing parallel-fibre terminals (Levenes et al., 2001; Delaney and Jahr, 2002) . While the AMPA-mediated activation of glutamate release from parallel/climbing fibres was unaffected by extracellular cGMP, the release of glutamate evoked by activation of kainate autoreceptors was inhibited by extracellular cGMP in the micromolar range. Evidence obtained in synaptosomes during static incubation (allowing accumulation of compounds in the extracellular compartment) and in slices (retaining complexity of neuronal and glial networks and allowing accumulation of compounds in the presynaptic receptor biophase) indicates that endogenously synthesized cGMP might be the physiological source for extracellular cGMP acting upon kainate autoreceptor.
This article has not been copyedited and formatted. The final version may differ from this version. Preparation of purified synaptosomes. After decapitation, the cerebellum was rapidly removed and placed in ice-cold medium, and nerve terminals (purified synaptosomes) were prepared as previously reported (Nakamura et al., 1993; Pedrazzi et al., 2006; Marcoli et al., 2008) . Briefly, the tissue was homogenized in 10 volumes of 0.32 M sucrose, buffered at pH 7.4 with Tris-HCl, using a glass-Teflon tissue grinder (clearance 0.25 mm). The homogenate was centrifuged (5 min, 1000 g at 4°C) to remove nuclei and debris, and the supernatant was gently stratified on a discontinuous Percoll gradient (2, 6, 10 and 20% v/v in Tris-buffered sucrose) and centrifuged at 33,500 g for 5 min. The layer between 10% and 20% Percoll was collected and washed by centrifugation. Purified synaptosomes ensure negligible contamination by non-neuronal cells (see Nakamura et al., 1993; Pedrazzi et al., 2006; Marcoli et al., 2008) ; in particular, cerebellar synaptosomes were found positive for the neuronal markers MAP-2 or β -tubulin III, and only scantly contamined by the glial marker GFAP; biochemical and functional data confirmed that cerebellar synaptosomes were largely free from glial elements (see Pedrazzi et al., 2006 (Israel and Whittaker, 1965; Raiteri et al., 1986) . In particular, most of the standard glutamate-releasing synaptosomes recovered from the adult rat cerebellum appear to originate from terminals of parallel fibres, the granule cell axons (see Vollenweider et al., 1990) .
Superfusion experiments.
Synaptosomes were transferred to parallel superfusion chambers at 37°C and superfused (0.5 ml/min) with standard medium aerated with 95% O 2 -5% CO 2 as previously described (Marcoli et al., 2008) . In these experimental conditions, monitoring release from a superfused synaptosomal monolayer (by removing any released compound and minimizing metabolism) avoids the receptor biophase and prevents indirect effects, thus enabling "nude" receptors to be exposed; in these conditions, only targets located on glutamatergic nerve terminals (when monitoring glutamate release) are selectively acted upon, allowing release-regulating presynaptic receptors to be characterized pharmacologically. Briefly, after 33-min superfusion, superfusate fractions were collected in 3 min samples (from the first fraction, basal1, B1 to B7); after 38 min of superfusion, synaptosomes were exposed (12 min) to ionotropic glutamate receptor agonists (and/or to the NO donors), to the depolarizing solution (9, 12 or 15 mM KCl; 2 min) or to the depolarizing agent 4-aminopyridine (4-AP; 100 μ M; 2 min). The effect of cyclothiazide, concanavalin A, of nucleotides, ODQ, probenecid or of the antagonists was evaluated on the agonist responses by adding the compounds 8 min before the agonist. In each experiment at least one chamber was used as a control for each condition and was superfused with standard medium or with medium appropriately modified. At the end of superfusion, the radioactivity in synaptosomes Glutamate determination. The amount of endogenous glutamate released in the fractions collected was measured by high-performance liquid chromatography, as previously described (Marcoli et al., 2008) . The analytical method involved automatic precolumn derivatization (Waters 715 ultra wisp; Milford, MA) with o-phthalaldehyde, followed by separation on a C18 reverse-phase chromatography column (Chrompack International, 10 cm x 4.6 mm, 3 μ m) and fluorimetric detection. Homoserine was used as an internal standard.
The detection limit was 100 fmol/μl. cGMP uptake. Synaptosomes were incubated (15 min at 37°C) in the presence of Log concentration-response relationships for the agonists and EC 50 (half-maximum effective concentrations) or IC 50 (half-maximum inhibitory concentrations) values were obtained by using a four-parameter logistic function-fitting routine (Sigma Plot software).
Means ± SEM of the numbers of experiments (n) are indicated throughout. Significance of the difference was analyzed by ANOVA followed by Student's t-test. The level of significance was set at p < 0.05.
Materials. [ Louis, MO).
When possible, drugs were dissolved in distilled water or in physiological medium.
Concanavalin A was dissolved in a buffer of 10 mM Hepes and 100 μ M CaCl 2 and then diluted 1:300. Stock solutions of cyclothiazide, CNQX, NS-102, ODQ or probenecid were prepared in dimethyl sulfoxide and diluted at least 1:1000 in physiological medium; stock GYKI 52466 solutions were freshly prepared in HCl 0.1 N and diluted 1:800; dimethyl sulfoxide diluted 1:1000 or HCl 0.1 N diluted 1:800 had no effect on (Fig. 1D ). The compound (S)-CPW 399, a full AMPA receptor agonist that significantly prevents receptor desensitization (Campiani et al., 2001) , mimicked the effect of AMPA, but exhibited greater efficacy than AMPA (EC 50 value 66.3 μ M; Fig. 1A ). Fig. 4A In the attempt to get an insight on physiological relevance of the effect of extracellular cGMP at kainate autoreceptor and on the possibility that intracellularly synthesized cGMP might be the physiological source for the extracellular cGMP response, additional experiments regarding the role of endogenously synthesized cGMP were performed in different experimental conditions (superfused synaptosomes, synaptosomes under static incubation, superfused slices). In particular, the possibility that endogenously produced cGMP might affect the response to kainate autoreceptor activation was investigated by assessing whether the response to kainate in the presence of the NO donor SNAP (at 1 μM concentration proved effective in producing cGMP in cerebellar slices from adult rat ; Marcoli et al, 2006a,b) , was affected when endogenous cGMP production was inhibited by the soluble guanylyl cyclase inhibitor ODQ (Garthwaite et al., 1995 ; see also Montoliu et al 1999; Marcoli et al, 2006a) . Furthermore, by considering that cyclic nucleotides can be transported across the plasma membrane by probenecid-sensitive organic anion transporters (Sager, 2004; Tjörnhammar et al., 1986 ) the response to kainate receptor activation in the presence of SNAP was compared to the response when cGMP efflux was blocked by probenecid.
In conditions where accumulation of substances released from presynaptic elements is This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 6A) ; the finding is consistent with our evidence that cGMP did not affect kainate receptor responses by acting at intracellular sites.
When substances produced intracellularly and transported across the membrane were (Fig. 6A,B,C) ; the releasing effect appeared unrelated to cGMP production, as it was unaffected by ODQ (100 μ M) or probenecid (500 μ M; Fig. 6A ,B,C). Notably, inhibition of cGMP production or transport (by 100 μM ODQ or 500 μM probenecid) significantly increased the response to kainate receptor activation (by kainate, in the presence of concanavalin A and of blockers of AMPA/NMDA receptors) in synaptosomes during static incubation or slices (Fig. 6B,C) , while leaved unaffected the response in superfused synaptosomes (Fig. 6A ). It could be therefore suggested that activation of Release-facilitatory kainate autoreceptors are present on cerebellar glutamatergic terminals. Presynaptic kainate receptors have been primarily identified on glutamatergic terminals (close to release sites; Pinheiro et al., 2005; Feligioni et al., 2006) in the rat hippocampus or cerebral cortex (Pittaluga et al., 1997; Bortolotto et al., 1999; Perkinton and Sihra, 1999; Rodriguez-Moreno and Sihra, 2004) . Here, we provide direct evidence of the presence of presynaptic kainate autoreceptors evoking spontaneous glutamate release from the terminals of cerebellar parallel/climbing fibres. The kainate receptormediated response was unmasked when AMPA receptors were blocked by GYKI 52466 and concanavalin A inhibited kainate receptor desensitization. Sensitivity to the GluR6 selective antagonist NS-102 (Verdoorn et al., 1994) , suggests that the kainate autoreceptor contains the GluR6 subunit. Our findings fit in with the expression of functional kainate receptors by granules (Smith et al., 1999; Pemberton et al., 1998) , with electrophysiological evidence for release-regulating kainate receptors on parallel fibres (Delaney and Jahr, 2002) and with the indication (obtained in GluR6-/-mice) that release-regulatory kainate receptors on rodent parallel fibres include GluR6 subunits (Crepel, 2007) . In the micromolar range extracellular cGMP competitively antagonized a kainate current in cultured granules (Poulopoulou and Nowak, 1998) and inhibited binding to a rat cerebellar kainate low-affinity site (Migani et al., 1997) . Although we found that the cGMP effect was overcome by increasing the kainate concentration, and extracellular cGMP shifted in a parallel way the kainate concentration-response relationship, Schild analysis yielded a less-than-unity slope suggesting that cGMP and kainate are not interacting competitively at a single receptor (sub)type on glutamatergic cerebellar terminals. One possibility would be that kainate effect is mediated by multiple kainate receptor subtypes, and cGMP binds with different affinity to these subtypes (see Kenakin, 1992) . In fact cerebellar granules express kainate receptors with different subunit composition (Belcher and Howe, 1997; Pemberton et al., 1998; Cui and Mayer, 1999) and both cGMP-insensitive and cGMP-sensitive kainate receptors (Poulopoulou and Nowak, 1998 (Paas et al, 1996 ; see also Migani et al, 1997; Poulopoulou and Nowak, 2008 and references therein) . On the other hand, being the effect specific for the cyclic nucleotide monophosphate cGMP, extracellular cGMP-signaling proteins (to be identified) might be the target of cGMP and might be involved in the inhibition of the kainate receptor(s). In fact, modulatory cyclic nucleotide-binding domains are present in proteins having diverse functions (see Shabb and Corbin, 1992; Francis et al, 2005) . Interestingly, receptors cannot be considered stand-alone entities, but can be regulated by accessory proteins: recently, extracellular domains of the transmembrane protein NETO2, which enhanced currents in GluR6-containing kainate receptors, were found to modulate kainate receptor activity (Zhang et al, 2008) .
A noteworthy point concerns the sites of cGMP production (and from which cGMP can be transported into the extracellular compartment) and the possibility that regulation of kainate autoreceptor response by extracellular cGMP might be of physiological relevance in the cerebellum. The concentration range of extracellular cGMP affecting the kainate autoreceptor response is high relative to the physiological levels indicated by in vivo microdialysis. Indeed, the extracellular cGMP level in the cerebellar cortex was estimated to be about 7 nM in basal conditions, increased up to 200 nM during glutamatergic pathway activation (Luo et al., 1994; Fedele and Raiteri, 1999 (Garthwaite, 2008; Gonzales et al, 2008; Ziolo et al, 2008) , and a NO-evoked cGMP-independent facilitation of neurotransmitter release from cerebellar parallel fibres was required during synaptic plasticity Qiu and Knopfel, 2007) .
Cerebellar nerve terminals could be a physiological source for cGMP affecting the kainate autoreceptor response; we cannot however exclude that glial or Purkinje cells, where cGMP accumulate following glutamate receptor/nitric oxide/guanylyl cyclase pathway activation or parallel fibre stimulation (Tsuyama et al., 1999; Hartell et al., 2001; Honda et al., 2001; Marcoli et al., 2006b ) and from which cGMP may be released (see Luo et al., 1994) might contribute as a source for extracellular cGMP.
Conclusions. Taken together, previous evidence and our findings suggest that a lowaffinity kainate receptor, most probably including the GluR6 subunit, is expressed in cerebellar granules, and functions as an autoreceptor which facilitates spontaneous glutamate release from parallel fibres; extracellular cGMP in the micromolar range behaves as an 
